Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vistagen TherapeuticsVTGN -3.56%16 3-Year EBITDA Growth Rate is 39.40% as of Jun. 2026, which is 37% above its 10-year median of 28.70. GuruFocus rates VTGN with a GF Score™ of 16/100. The stock has 3 warning signs investors should review. Among 1,130 Biotechnology companies, Vistagen Therapeutics ranks better than 77.61% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 39.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 28.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 38.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Vistagen Therapeutics was 68.00% per year. The lowest was -658.60% per year. And the median was 28.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Vistagen Therapeutics 3-Year EBITDA Growth Rate Related Terms
VTGN vs ASBP, CRIS, TOVX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Vistagen Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 39.40% mean?
Vistagen Therapeutics (VTGN) has a 3-Year EBITDA Growth Rate of 39.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vistagen Therapeutics and its competitors. This is 37% above median its historical median of 28.70. According to the industry distribution chart, Vistagen Therapeutics ranks #253 out of 1130 companies in the Biotechnology industry, placing it in the top 22.4%.
Is Vistagen Therapeutics' 3-Year EBITDA Growth Rate too high?
Vistagen Therapeutics' current 3-Year EBITDA Growth Rate of 39.40% is 37% above median its 10-year median of 28.70. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Vistagen Therapeutics' value of 39.40% is 165.3% above this industry median. Based on the distribution chart, Vistagen Therapeutics ranks #253 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vistagen Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' 3-Year EBITDA Growth Rate compare to ASBP and CRIS?
According to the Biotechnology industry distribution chart, Vistagen Therapeutics ranks #253 out of 1130 companies for 3-Year EBITDA Growth Rate. This places Vistagen Therapeutics in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. Vistagen Therapeutics' value of 39.40% is 165.3% above this benchmark. While the company's 10-year median is 28.70 vs. the industry median of 14.85, Vistagen Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistagen Therapeutics's current 3-Year EBITDA Growth Rate of 39.40% is 165.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vistagen Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistagen Therapeutics's current 3-Year EBITDA Growth Rate is 39.40%, which is 37% above median its own 10-year median of 28.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Vistagen Therapeutics (VTGN) has a current 3-Year EBITDA Growth Rate of 39.40%. The current 3-Year EBITDA Growth Rate is 39.40%, which is 37% above median its 10-year median of 28.70 and 165.3% above the Biotechnology industry median of 14.85. Vistagen Therapeutics' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Vistagen Therapeutics (VTGN), the current 3-Year EBITDA Growth Rate is 39.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
16GF Score
Get the complete analysis for VTGN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTGN has been successfully added to your 
